June 27, 2018 - 7:50 AM EDT
Print Email Article Font Down Font Up Charts






Detailed Research: Economic Perspectives on Comerica, Vanda Pharmaceuticals, Acadia Healthcare, The Charles Schwab, Ares Capital, and EQT — What Drives Growth in Today's Competitive Landscape

NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Comerica Incorporated (NYSE:CMA), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Acadia Healthcare Company, Inc. (NASDAQ:ACHC), The Charles Schwab Corporation (NYSE:SCHW), Ares Capital Corporation (NASDAQ:ARCC), and EQT Corporation (NYSE:EQT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CMA DOWNLOAD: http://Fundamental-Markets.com/register/?so=CMA
VNDA DOWNLOAD: http://Fundamental-Markets.com/register/?so=VNDA
ACHC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACHC
SCHW DOWNLOAD: http://Fundamental-Markets.com/register/?so=SCHW
ARCC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARCC
EQT DOWNLOAD: http://Fundamental-Markets.com/register/?so=EQT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Comerica Incorporated (NYSE:CMA), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Acadia Healthcare Company, Inc. (NASDAQ:ACHC), The Charles Schwab Corporation (NYSE:SCHW), Ares Capital Corporation (NASDAQ:ARCC), and EQT Corporation (NYSE:EQT) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed June 25th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

COMERICA INCORPORATED (CMA) REPORT OVERVIEW

Comerica's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Comerica reported interest income of $590.00MM vs $496.00MM (up 18.95%) and basic earnings per share $1.62 vs $1.15 (up 40.87%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Comerica reported interest income of $2,182.00MM vs $1,909.00MM (up 14.30%) and basic earnings per share $4.23 vs $2.74 (up 54.38%). Comerica is expected to report earnings on July 17th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $1.15. The estimated EPS forecast for the next fiscal year is $7.61 and is expected to report on January 15th, 2019.

To read the full Comerica Incorporated (CMA) report, download it here: http://Fundamental-Markets.com/register/?so=CMA

-----------------------------------------

VANDA PHARMACEUTICALS INC. (VNDA) REPORT OVERVIEW

Vanda Pharmaceuticals' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Vanda Pharmaceuticals reported revenue of $43.59MM vs $37.42MM (up 16.51%) and basic earnings per share $0.07 vs -$0.17. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Vanda Pharmaceuticals reported revenue of $165.08MM vs $146.02MM (up 13.06%) and basic earnings per share -$0.35 vs -$0.41. Vanda Pharmaceuticals is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.03. The estimated EPS forecast for the next fiscal year is $0.55 and is expected to report on February 13th, 2019.

To read the full Vanda Pharmaceuticals Inc. (VNDA) report, download it here: http://Fundamental-Markets.com/register/?so=VNDA

-----------------------------------------

ACADIA HEALTHCARE COMPANY, INC. (ACHC) REPORT OVERVIEW

Acadia Healthcare's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Acadia Healthcare reported revenue of $742.24MM vs $679.19MM (up 9.28%) and basic earnings per share $0.58 vs $0.40 (up 45.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Acadia Healthcare reported revenue of $2,836.32MM vs $2,810.91MM (up 0.90%) and basic earnings per share $2.30 vs $0.07 (up 3,185.71%). Acadia Healthcare is expected to report earnings on July 26th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.66. The estimated EPS forecast for the next fiscal year is $2.85 and is expected to report on February 20th, 2019.

To read the full Acadia Healthcare Company, Inc. (ACHC) report, download it here: http://Fundamental-Markets.com/register/?so=ACHC

-----------------------------------------

THE CHARLES SCHWAB CORPORATION (SCHW) REPORT OVERVIEW

The Charles Schwab's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, The Charles Schwab reported revenue of $2,398.00MM vs $2,081.00MM (up 15.23%) and basic earnings per share $0.55 vs $0.39 (up 41.03%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, The Charles Schwab reported revenue of $8,618.00MM vs $7,478.00MM (up 15.24%) and basic earnings per share $1.63 vs $1.32 (up 23.48%). The Charles Schwab is expected to report earnings on July 17th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.39. The estimated EPS forecast for the next fiscal year is $2.87 and is expected to report on January 16th, 2019.

To read the full The Charles Schwab Corporation (SCHW) report, download it here: http://Fundamental-Markets.com/register/?so=SCHW

-----------------------------------------

ARES CAPITAL CORPORATION (ARCC) REPORT OVERVIEW

Ares Capital's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Ares Capital reported revenue of $317.00MM vs $275.00MM (up 15.27%) and basic earnings per share $0.57 vs $0.28 (up 103.57%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ares Capital reported revenue of $1,160.00MM vs $1,012.00MM (up 14.62%) and basic earnings per share $1.57 vs $1.51 (up 3.97%). Ares Capital is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.34. The estimated EPS forecast for the next fiscal year is $1.65 and is expected to report on February 12th, 2019.

To read the full Ares Capital Corporation (ARCC) report, download it here: http://Fundamental-Markets.com/register/?so=ARCC

-----------------------------------------

EQT CORPORATION (EQT) REPORT OVERVIEW

EQT's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, EQT reported revenue of $1,433.58MM vs $894.17MM (up 60.33%) and basic earnings per share -$5.99 vs $0.95. For the twelve months ended December 31st, 2017 vs December 31st, 2016, EQT reported revenue of $3,378.02MM vs $1,608.35MM (up 110.03%) and basic earnings per share $8.05 vs -$2.71. EQT is expected to report earnings on July 26th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.06. The estimated EPS forecast for the next fiscal year is $2.01 and is expected to report on February 21st, 2019.

To read the full EQT Corporation (EQT) report, download it here: http://Fundamental-Markets.com/register/?so=EQT

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Primary Logo


Source: GlobeNewswire (June 27, 2018 - 7:50 AM EDT)

News by QuoteMedia
www.quotemedia.com
Tags:

Legal Notice